home

clinical

inflammation-infection

Clinical

Articles

Foresight Biotherapeutics, Inc. has announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a highly regarded Ad5 NZW rabbit model of adenoviral conjunctivitis.

Clinical improvement in adenoviral conjunctivitis model

BD OcuSeal Liquid Ocular Bandage, a fully synthetic protective barrier to be used for post-surgical, post-traumatic and non-traumatic ocular conditions, has been launched in Europe by BD Medical?Ophthalmic Systems.

Liquid ocular bandage launched in Europe

According to research analysts it is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers.

Novagali technologies allow greater drug access to the posterior of the eye

The fluocinolone acetonide (Retisert; Bausch & Lomb) surgical implant can prevent blindness in cases of sympathetic ophthalmia (SO), according to research at the University of Iowa, US.

Retisert implant in sympathetic ophthalmia

There is an association between uveal and a variety of skin melanomas, according to study results published in the March issue of Ophthalmology.

Link between skin cancer and eye cancer

ESBATech AG, a developer of antibody fragment therapeutics, has initiated a Phase IIa study in patients with acute anterior uveitis, designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105.

Uveitis study enters Phase IIa

Fungus and microbial infection are the most common causes of infectious scleritis, according to study conclusions published in the February issue of Eye.

Causes of infectious scleritis

ESBA105, an anti-TNF alpha antibody fragment designed to reduce inflammation in patients undergoing cataract surgery, has begun a Phase Ib/IIa trial, according to an announcement from ESBATech AG, the antibody's developer.

Anti-inflammatory enters Phase I/II

A New Drug Application (NDA) for ganciclovir ophthalmic gel 0.15% against herpetic keratitis, submitted by Sirion Therapeutics, Inc, has been accepted for review by the FDA.

Ocular herpes drug under FDA review

Professor Scott Cousins explains how we can use our knowledge of drusen formation to find new ways to combat dry age-related macular degeneration.

Inflammation & Infection

New content coming soon, please check back later.